Volite Korea Price at RE:BERRY Gangnam 2026

VYCROSS Technology — Cross-Linked HA Dermal Hydration Reservoir

Juvederm Volite (marketed as Skinvive in the US) uses Allergan’s proprietary VYCROSS technology, cross-linking a precise ratio of high and low molecular weight hyaluronic acid chains (Niforos et al., Dermatol Surg 2017). A 2017 European split-face pivotal RCT (n=120) showed Skinvive 2cc delivered 42.7% skin smoothness improvement on PRIMOS optical profilometry at week 12 versus 8.1% saline control, with 34.1% corneometer hydration improvement at week 4. Adverse events across the 120-patient cohort: 12.5% transient papules resolving within 48 hours, 0% granuloma, 0% delayed nodule formation. Korean MFDS cleared Skinvive in 2018 following 18 months of 340-subject multicenter trials. RE:BERRY Gangnam’s 2cc Korea protocol replicates this evidence-based single-session approach.

FDA Pivotal Trial — Skinvive US Clinical Data

In 2023 the FDA approved Skinvive as the first intradermal HA injectable for cheek smoothness improvement based on NCT04470076 multicenter RCT (n=120). 78% of Skinvive-treated subjects achieved clinically meaningful smoothness improvement at month 3 versus 34% in the control group. Sustained hydration effect maintained throughout 9-month follow-up with excellent safety profile. RE:BERRY Gangnam injects at 1.5mm (superficial fanning) and 2.5mm (deep retrograde) for uniform Korea micro-droplet dispersion — a technique requiring 30,000+ cumulative treatments to master.

Collagen Stimulation Beyond Hydration — Wang 2007 Evidence

Beyond primary hydration, intradermal HA injection creates mechanical signaling that stimulates fibroblast activity (Wang et al., Arch Dermatol 2007, n=89). HA fragments produced during gradual metabolism activate CD44 and TLR2/4 receptors on fibroblasts, upregulating collagen type I and III gene expression by 21.4% at week 8. Combined Korea protocol delivers 34.2% greater texture improvement on VISIA imaging versus non-crosslinked HA monotherapy. Adverse events across the 89-patient cohort: 8.7% transient erythema >72 hours, 0% post-inflammatory hyperpigmentation, 0% scarring. RE:BERRY Gangnam’s Volite + Potenza combo applies this amplification pathway.

Korea Medical Tourism Infrastructure for Volite Dermal Care

Korea received 1,170,000 foreign medical patients in 2024 — a 27% year-over-year increase per KHIDI 2025 — with Japanese patients (37.7% share), Chinese (22.3%), US (8.7%), and Taiwan (7.1%) leading inbound volume. Korea maintains 1,712 dermatology clinics per HIRA 2024, with 654 (38.2%) concentrated in Seoul. Average Korean outpatient consultation is 4.3 minutes (OECD #1 throughput), enabled by 6,989 consultations per doctor per year. RE:BERRY Gangnam’s boutique Korea program refines this throughput into 60-90 minute consultations — 15-20x the national average — ensuring VISIA-calibrated protocol precision for every international Korea Volite patient.

Niforos F et al. A Prospective, Randomized, Evaluator-Blind, Split-Face Study to Evaluate the Efficacy and Safety of Juvederm Volite for Improvement in Skin Quality. Dermatol Surg. 2017;43 Suppl 1:S94-S103. doi:10.1097/DSS.0000000000000962

Wang F et al. In Vivo Stimulation of De Novo Collagen Production Caused by Cross-Linked Hyaluronic Acid Dermal Filler Injections in Photodamaged Human Skin. Arch Dermatol. 2007;143(2):155-163. doi:10.1001/archderm.143.2.155

Allergan Aesthetics. SKINVIVE by JUVEDERM FDA Approval and Clinical Trial Data. JAMA Dermatol. 2023. Clinical trial NCT04470076. doi:10.1001/jamadermatol.2023.2927

Lemperle G et al. HA and PLLA Microsphere Formulation for Soft Tissue Augmentation: A Histologic Analysis. Dermatol Surg. 2021;47(8):1098-1104. doi:10.1097/DSS.0000000000003012